Get the Stockscreener App
0.2232
5.33%
0.0113
Pre-market:
.22
-0.0032
-1.43%
Theriva Biologics Inc stock is traded at $0.2232, with a volume of 9.70M.
It is up +5.33% in the last 24 hours and up +11.71% over the past month.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
See More
Previous Close:
$0.2119
Open:
$0.2152
24h Volume:
9.70M
Relative Volume:
0.71
Market Cap:
$10.24M
Revenue:
-
Net Income/Loss:
$-23.74M
P/E Ratio:
-0.0553
EPS:
-4.0366
Net Cash Flow:
$-16.70M
1W Performance:
+23.31%
1M Performance:
+11.71%
6M Performance:
-42.71%
1Y Performance:
-81.85%
1-Day Range:
$0.2065
$0.235
1-Week Range:
$0.1771
$0.2801
52-Week Range:
$0.1628
$1.50
Theriva Biologics Inc Stock (TOVX) Company Profile
Name
Theriva Biologics Inc
Sector
Industry
Phone
301 417 4364
Address
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
0.2232 | 9.72M | 0 | -23.74M | -16.70M | -4.0366 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Theriva Biologics Inc Stock (TOVX) Latest News
Portfolio Recap: Does Theriva Biologics Inc have strong EBITDA margins2026 Movers & Weekly Top Gainers Trade List - baoquankhu1.vn
Maxim Group Maintains Theriva Biologics(TOVX.US) With Hold Rating - Moomoo
Maxim Group Maintains Theriva Biologics(TOVX.US) With Hold Rating, Announces Target Price $0.22 - Moomoo
Theriva Biologics announces outcome of Type B End-of-Phase 2 meeting with FDA - TipRanks
Theriva Biologics Receives FDA Agreement to Advance VCN-01 to Phase 3 Trial for Metastatic Pancreatic Cancer 1 - Minichart
Theriva Biologics Announces Positive End-Of-Phase 2 Meeting With U.S. FDA Regarding The Design Of A Phase 3 Trial Of VCN-01 In Metastatic Pancreatic Ductal Adenocarcinoma - marketscreener.com
Theriva™ Biologics reports full-year 2025 operational highlights and financial results - MSN
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results - Stocktwits
Theriva Biologics (TOVX) Advances Phase 3 Clinical Trial Plans f - GuruFocus
Theriva Biologics Advances VCN-01 Into Pivotal Phase 3 - TipRanks
Theriva gets FDA alignment on phase 3 trial design for VCN-01 - Investing.com Canada
Theriva Biologics aligns with FDA on Phase 3 VCN-01 design for metastatic PDAC - TradingView
Theriva Biologics (NYSE: TOVX) gains FDA alignment on pivotal VCN-01 Phase 3 in metastatic PDAC - Stock Titan
Theriva pushes pancreatic cancer drug VCN-01 toward Phase 3 - Stock Titan
If You Invested $1,000 in THERIVA BIOLOGICS INC (TOVX) - Stock Titan
Theriva Biologics (TOVX) Registration Filing Summary - Quartr
Chart Watch: Is Theriva Biologics Inc showing insider buying2026 Technicals & Target Return Focused Stock Picks - baoquankhu1.vn
TOVX Stock Price, Quote & Chart | THERIVA BIOLOGICS INC (NYSEARCA:TOVX) - ChartMill
Aug Swings: Will Theriva Biologics Inc outperform its industry peers2026 Key Lessons & Risk Managed Investment Signals - baoquankhu1.vn
Theriva Biologics (NYSE: TOVX) puts 16.2M warrant share issuance to vote - Stock Titan
Theriva Biologics, Inc. (TOVX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Theriva Biologics Reports Full-Year 2025 Operational Highlights and Financial Results - Bitget
TOVX Reports Strong Cash Position and Funding Plans for Clinical Trials - GuruFocus
Theriva 10-K: Net loss $23.74M, EPS $(2.08); Operating loss $24.05M - TradingView
Theriva Biologics reports $13.1M year-end cash, $25.2M net loss for 2025 - TradingView
Form 10-K Theriva Biologics, Inc. For: Dec 31 - StreetInsider
Theriva Biologics (NYSE: TOVX) details 2025 loss and cash runway into 2027 - Stock Titan
Cancer drug developer Theriva inks SYN-020 deal up to $38M - Stock Titan
TOVX Advances Oncology Pipeline with Strategic Licensing and Cli - GuruFocus
Theriva Biologics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Aug Mood: Can Theriva Biologics Inc maintain sales growthStock Surge & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Aug Shorts: Can Theriva Biologics Inc maintain sales growthAnalyst Upgrade & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026 - Stocktwits
TOVX Should I Buy - Intellectia AI
TOVX SEC FilingsTHERIVA BIOLOGICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications - Stocktwits
TOVX Technical Analysis & ETF Price Forecast - Intellectia AI
Is Theriva Biologics Inc. stock a top pick in earnings season2025 Fundamental Recap & Intraday High Probability Setup Alerts - mfd.ru
TOVX Theriva Biologics AMEX pre-market +12% Feb 20 2026: Most active - Meyka
$30M Revenue Rocket, Super Spiders, and Biotech Patent Blitz Launch Morning Momentum - GlobeNewswire Inc.
Aug Update: What are Theriva Biologics Incs technical support levelsJuly 2025 News Drivers & Stepwise Trade Execution Plans - baoquankhu1.vn
Theriva Biologics licenses Syn-020 to Rasayana Therapeutics for multiple indications - marketscreener.com
Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications - TradingView
Theriva Biologics (TOVX) Licenses SYN-020 to Rasayana Therapeuti - GuruFocus
Theriva Licenses SYN-020, Refocuses on Cancer Pipeline - TipRanks
Theriva Biologics Inc (referred to as Theriva Biologics) has successfully received a $300,000 upfront payment at the time of signing the agreement. - Bitget
Theriva Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications - Bitget
How Theriva Biologics Inc. stock reacts to Fed rate cutsWeekly Profit Recap & Daily Price Action Insights - mfd.ru
Published on: 2026-02-14 06:14:36 - mfd.ru
Theriva Biologics Faces Delay in Warrant Approval Meeting - The Globe and Mail
Theriva Biologics Inc Stock (TOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Cap:
|
Volume (24h):